Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Parameter Space and Potential for Biomarker Development in 25 Years of Fmri Drug Cue Reactivity: A Systematic Review Publisher Pubmed



Sangchooli A1 ; Zarebidoky M2, 3 ; Fathi Jouzdani A3 ; Schacht J4 ; Bjork JM5 ; Claus ED6 ; Prisciandaro JJ7 ; Wilson SJ8 ; Wustenberg T9 ; Potvin S10 ; Ahmadi P11 ; Bach P12 ; Baldacchino A13 ; Beck A14, 15 Show All Authors
Authors
  1. Sangchooli A1
  2. Zarebidoky M2, 3
  3. Fathi Jouzdani A3
  4. Schacht J4
  5. Bjork JM5
  6. Claus ED6
  7. Prisciandaro JJ7
  8. Wilson SJ8
  9. Wustenberg T9
  10. Potvin S10
  11. Ahmadi P11
  12. Bach P12
  13. Baldacchino A13
  14. Beck A14, 15
  15. Brady KT7
  16. Brewer JA16
  17. Childress AR17
  18. Courtney KE18
  19. Ebrahimi M3
  20. Filbey FM19
  21. Garavan H20
  22. Ghahremani DG21
  23. Goldstein RZ22
  24. Goudriaan AE23, 24
  25. Grodin EN21
  26. Hanlon CA25, 26
  27. Haugg A27
  28. Heilig M28
  29. Heinz A15
  30. Holczer A29
  31. Van Holst RJ30
  32. Joseph JE31
  33. Juliano AC20
  34. Kaufman MJ32
  35. Kiefer F12
  36. Khojasteh Zonoozi A3
  37. Kuplicki RT33
  38. Leyton M34
  39. London ED21
  40. Mackey S20
  41. Mcclernon FJ35
  42. Mellick WH7
  43. Morley K36
  44. Noori HR37
  45. Oghabian MA38
  46. Oliver JA39
  47. Owens M20
  48. Paulus MP33
  49. Perini I28
  50. Rafei P3
  51. Ray LA21
  52. Sinha R40
  53. Smolka MN41
  54. Soleimani G2
  55. Spanagel R42
  56. Steele VR40
  57. Tapert SF18
  58. Vollstadtklein S12
  59. Wetherill RR17
  60. Witkiewitz K43
  61. Yuan K44
  62. Zhang X45
  63. Verdejogarcia A46
  64. Potenza MN41
  65. Janes AC47
  66. Kober H40
  67. Zilverstand A2
  68. Ekhtiari H2, 33

Source: JAMA Psychiatry Published:2024


Abstract

Importance: In the last 25 years, functional magnetic resonance imaging drug cue reactivity (FDCR) studies have characterized some core aspects in the neurobiology of drug addiction. However, no FDCR-derived biomarkers have been approved for treatment development or clinical adoption. Traversing this translational gap requires a systematic assessment of the FDCR literature evidence, its heterogeneity, and an evaluation of possible clinical uses of FDCR-derived biomarkers. Objective: To summarize the state of the field of FDCR, assess their potential for biomarker development, and outline a clear process for biomarker qualification to guide future research and validation efforts. Evidence Review: The PubMed and Medline databases were searched for every original FDCR investigation published from database inception until December 2022. Collected data covered study design, participant characteristics, FDCR task design, and whether each study provided evidence that might potentially help develop susceptibility, diagnostic, response, prognostic, predictive, or severity biomarkers for 1 or more addictive disorders. Findings: There were 415 FDCR studies published between 1998 and 2022. Most focused on nicotine (122 [29.6%]), alcohol (120 [29.2%]), or cocaine (46 [11.1%]), and most used visual cues (354 [85.3%]). Together, these studies recruited 19311 participants, including 13812 individuals with past or current substance use disorders. Most studies could potentially support biomarker development, including diagnostic (143 [32.7%]), treatment response (141 [32.3%]), severity (84 [19.2%]), prognostic (30 [6.9%]), predictive (25 [5.7%]), monitoring (12 [2.7%]), and susceptibility (2 [0.5%]) biomarkers. A total of 155 interventional studies used FDCR, mostly to investigate pharmacological (67 [43.2%]) or cognitive/behavioral (51 [32.9%]) interventions; 141 studies used FDCR as a response measure, of which 125 (88.7%) reported significant interventional FDCR alterations; and 25 studies used FDCR as an intervention outcome predictor, with 24 (96%) finding significant associations between FDCR markers and treatment outcomes. Conclusions and Relevance: Based on this systematic review and the proposed biomarker development framework, there is a pathway for the development and regulatory qualification of FDCR-based biomarkers of addiction and recovery. Further validation could support the use of FDCR-derived measures, potentially accelerating treatment development and improving diagnostic, prognostic, and predictive clinical judgments. © 2024 American Medical Association. All rights reserved.
Other Related Docs